

Supplement table 1: Cancer age-standardized incidence rates per 100,000 person-years and average annual percent change (AAPC) by cancer sites and year of diagnosis among men, in HCMC 2004- 2013.

Cancer sites (ICD-10)	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	AAPC (95%CI)	Significant Joinpoint (year)
Oral cavity (C0-C8)	5.1	5.6	5.2	5.0	4.6	6.4	6.4	4.9	6.3	5.3	1.2 (-1.9, 4.5)	No
Pharynx (C9-14)	9.8	6.6	6.7	8.8	8.1	8.0	8.3	7.0	7.1	7.6	-1.4 (-4.4, 1.7)	No
Oesophagus (C15)	4.0	4.3	3.8	4.6	4.0	4.0	4.0	5.1	4.2	4.0	0.6 (-2.0, 3.2)	No
Stomach (C16)	14.7	9.8	12.6	11.9	9.3	12.1	10.9	8.6	9.0	8.1	-4.8 (-7.9, -1.6)	No
Colorectum (C18-20)	15.7	12.1	14.1	16.3	14.5	20.9	18.9	21.5	21.8	23.4	6.6 (3.7, 9.4)	No
Liver (C22)	27.4	21.6	24.8	25.2	18.2	26.3	22.7	24.3	16.5	16.9	-3.6 (-7.3, 0.3)	No
Pancreas (C25)	2.2	1.5	1.9	1.9	2.1	2.4	1.6	1.5	1.1	1.2	-5.4 (-10.5, 0.0)	No
Larynx (C32)	4.4	3.7	4.5	5.2	4.3	5.0	4.0	4.5	3.6	4.6	-0.4 (-3.7, 2.9)	No
Lung & bronchus (C33-34)	29.4	18.3	21.7	30.7	21.1	26.5	24.5	33.2	31.8	29.5	3.1 (-1.3, 7.6)	No
Other skin (C44)	2.7	3.3	3.5	2.3	2.1	3.3	3.1	2.5	3.6	4.7	3.8 (-1.7, 9.6)	No
Breast (C50)	0.7	0.4	0.3	0.7	0.8	0.5	0.3	0.6	0.6	0.6	-0.7 (-7.9, 7.0)	No
Prostate (C61)	5.5	4.3	5.4	5.3	5.4	4.2	4.7	4.3	4.9	5.3	-0.7 (-3.3, 2.0)	No
Kidney (C64)	0.9	1.1	1.5	1.5	1.1	1.8	1.8	1.7	1.4	2.0	5.8 (1.1, 10.8)	No
Bladder (C67)	2.1	1.6	1.6	1.7	2.0	2.3	3.3	3.5	4.2	3.4	11.4 (6.3, 16.7)	No
Brain, nervous system (C70-72)	1.7	1.4	2.0	2.8	2.0	2.2	1.7	2.4	1.4	1.6	-1.1 (-7.1, 5.3)	No
Thyroid (C73)	2.0	1.4	1.3	2.4	2.4	2.3	1.9	2.7	2.3	2.4	4.3 (-0.7, 9.5)	No
Non-Hodgkin lymphoma (C82-85, C96)	4.7	4.5	4.5	4.1	3.4	4.0	4.1	3.9	4.4	3.6	-1.7 (-3.8, 0.5)	No
Leukaemia (C91-95)	4.1	3.0	5.1	3.7	4.5	3.3	2.7	3.6	3.5	2.9	-3.5 (-8, 1.3)	No
Others	9.4	9.3	9.5	12.3	11.1	10.5	11.0	9.8	8.5	8.1	-1.6 (-5, 1.9)	No
All (C00-C96 without C44)	143.7	110.5	126.2	144.1	119.0	142.6	133.0	143.0	132.3	130.6	0.4 (-1.8, 2.7)	No

*AAPCs 95% CI indicated a significant difference from 0 at $\alpha=0.05$ level.

Supplement table 2: Cancer age-standardized incidence rates per 100,000 person-years and average annual percent change (AAPC) by cancer sites and year of diagnosis among women, in HCMC 2004- 2013.

Cancer sites (ICD-10)	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	AAPC (95% CI)	Significant Joinpoint (year)
Oral cavity (C0-C8)	3.0	2.0	2.7	2.3	2.5	2.2	2.1	1.9	1.8	2.3	-3.3 (-6.5, -0.1)	No
Pharynx (C9-14)	2.1	1.9	1.3	2.4	1.7	1.8	2.1	1.8	1.4	1.7	-1.9 (-6.2, 2.6)	No
Oesophagus (C15)	0.7	0.3	0.6	0.3	0.3	0.1	0.2	0.4	0.1	0.3	-9.4 (-18.4, 0.6)	No
Stomach (C16)	6.1	6.1	5.8	5.3	4.4	5.6	4.4	3.9	3.8	3.8	-5.7 (-7.7, -3.6)	No
Colorectun (C18-21)	8.6	9.3	9.2	10.3	9.4	12.2	13.1	13.0	11.8	13.0	4.9 (2.7, 7.2)	No
Liver (C22)	6.4	5.5	7.0	6.0	5.0	6.4	6.2	5.5	4.3	4.6	-3.4 (-6.5, -0.1)	No
Pancreas (C25)	1.1	1.2	1.1	1.2	1.4	1.2	1.4	1.1	1.2	1.1	-0.4 (-3.3, 2.7)	No
Larynx (C32)	0.3	0.3	0.2	0.1	0.4	0.3	0.4	0.1	0.2	0.2	-0.6 (-11.4, 11.5)	No
Lung & bronchus (C33-34)	11.7	9.2	8.0	11.9	7.2	8.5	9.2	12.1	10.6	10.5	0.9 (-3.5, 5.4)	No
Other skin (C44)	3.8	2.7	3.0	2.9	2.5	2.4	2.0	2.1	3.4	3.9	1.2 (-4.7, 7.5)	Yes (2010)
Breast (C50)	22.5	19.7	23.5	23.8	20.6	23.9	26.2	26.1	26.8	26.1	2.7 (1.0, 4.5)	No
Cervix uteri (C53)	16.6	16.1	15.9	18.1	17.2	17.2	13.7	15.3	15.5	14.5	-1.5 (-3.4, 0.4)	No
Corpus uteri (C54)	2.4	2.0	4.7	2.8	4.2	4.2	3.9	4.1	4.0	3.6	3.2 (-2.9, 9.6)	No
Ovary etc. (C56-57)	5.4	3.4	4.9	5.9	6.5	5.8	5.2	5.5	6.5	6.0	2.7 (-1.0, 6.6)	No
Kidney (C64)	0.8	0.7	0.8	0.7	0.7	0.7	0.9	0.9	0.8	0.9	2.4 (-0.3, 5.2)	No
Bladder (C67)	0.4	0.3	0.5	0.4	0.3	0.6	0.3	0.5	0.6	0.6	6.1 (-0.3, 12.8)	No
Brain, nervous system (C70-72)	0.8	1.2	2.3	1.6	1.8	1.7	1.0	1.5	1.5	1.1	5.6 (-10.3, 24.3)	No
Thyroid (C73)	4.6	4.6	7.0	7.7	8.1	8.3	8.5	10.3	9.4	9.9	7.7 (4.4, 11.1)	No
Non-Hodgkin lymphoma (C82-85, C96)	3.2	2.8	3.1	2.8	1.6	1.8	2.8	2.8	2.4	2.0	-3.4 (-7.9, 1.4)	No
Leukaemia (C91-95)	3.5	2.6	3.0	2.7	2.9	2.8	2.7	2.0	2.5	2.0	-4.6 (-7.4, -1.8)	No
Others	6.6	5.6	5.2	9.6	6.5	7.6	7.4	6.6	5.5	5.8	-1.2 (-6.4, 4.2)	No
All (C00-C96 without C44)	106.6	94.6	106.8	115.8	102.8	113.2	111.9	115.4	110.9	110.0	1.0 (-0.4, 2.3)	No

*AAPCs 95% CI indicated a significant difference from 0 at alpha=0.05 level.

Supplement table 3: Cancer age-standardized incidence rates per 100,000 person-years and average annual percent change (AAPC) by cancer sites and year of diagnosis among men, in Hanoi 2004- 2012.

Cancer sites (ICD-10)	2004	2005	2006	2007	2008	2009	2010	2011	2012	AAPC (95%CI)	Significant Joinpoint (year)
Oral cavity (C0-C8)	5.0	5.0	6.3	4.6	7.8	6.2	7.1	6.2	6.8	3.3 (-1.2, 8.1)	No
Pharynx (C9-14)	13.3	12.6	14.4	12.0	17.3	17.7	19.2	19.7	14.9	4.3 (-0.7, 9.5)	No
Oesophagus (C15)	10.9	13.9	13.6	14.5	18.3	15.7	17.9	18.6	19.7	6.1 (3.8, 8.4)	No
Stomach (C16)	27.7	33.5	33.3	30.8	34.1	39.5	34.7	33.0	26.5	-0.5 (-4.5, 3.7)	No
Colorectum (C18-20)	14.0	16.3	19.2	19.2	25.8	25.1	24.0	26.6	22.5	5.6 (1.1, 10.2)	No
Liver (C22)	21.7	22.7	17.6	21.1	22.1	29.0	26.4	28.4	20.6	2.4 (-2.6, 7.7)	No
Pancreas (C25)	1.7	1.6	1.3	1.7	2.3	2.9	2.8	2.7	2.3	7.1 (0.6, 14.1)	No
Larynx (C32)	2.9	2.8	4.1	3.2	4.9	3.2	5.9	5.2	2.1	3.6 (-8.9, 17.9)	No
Lung & bronchus (C33-34)	42.9	45.7	40.3	48.7	43.4	60.1	61.6	61.8	52.5	4.5 (0.5, 8.5)	No
Other skin (C44)	1.9	1.3	1.8	2.6	3.1	3.1	2.2	2.3	1.6	0.1 (-8.9, 10)	No
Breast (C50)	1.4	1.5	1.1	1.0	1.2	1.7	1.6	1.5	1.7	3.8 (-0.9, 8.8)	No
Prostate (C61)	2.8	3.9	5.8	5.4	5.1	5.2	5.6	6.6	4.9	4.3 (-1.6, 10.6)	No
Kidney (C64)	0.5	1.0	1.0	1.3	1.6	1.7	1.6	1.8	1.3	7.7 (-0.6, 16.6)	No
Bladder (C67)	2.9	4.8	4.1	4.5	4.0	5.0	4.3	4.9	3.1	-0.1 (-6.1, 6.2)	No
Brain, nervous system (C70-72)	1.8	1.4	0.9	2.2	2.2	2.5	2.0	2.6	1.7	3.6 (-4.1, 11.9)	No
Thyroid (C73)	1.6	2.8	3.4	2.1	3.3	3.4	2.8	3.8	3.6	5.4 (-0.5, 11.6)	No
Non-Hodgkin lymphoma (C82-85, C96)	7.0	6.1	8.2	6.6	8.3	7.3	6.3	6.7	5.7	-2.3 (-5.9, 1.6)	No
Leukaemia (C91-95)	4.2	5.5	5.9	6.2	5.7	11.0	3.3	4.6	2.4	-5.3 (-19.1, 10.9)	No
Others	13.3	14.0	12.8	11.8	17.4	19.2	15.4	16.5	14.4	2.1 (-2.3, 6.7)	No
All (C00-C96 without C44)	175.6	195.2	193.5	197.1	224.9	256.4	242.7	251.0	206.8	3.0 (-0.5, 6.6)	No

*AAPCs 95% CI indicated a significant difference from 0 at alpha=0.05 level.

Supplement table 4: Cancer age-standardized incidence rates per 100,000 person-years and average annual percent change (AAPC) by cancer sites and year of diagnosis among women, in Hanoi 2004- 2012.

Cancer sites (ICD-10)	2004	2005	2006	2007	2008	2009	2010	2011	2012	AAPC (95% CI)	Significant Joinpoint (year)
Oral cavity (C0-C8)	2.8	2.4	3.6	2.3	5.4	3.2	3.3	3.0	3.1	0.3 (-7.6, 8.8)	No
Pharynx (C9-14)	3.2	4.2	5.3	3.6	7.3	6.8	6.0	4.5	4.0	0.5 (-8.7, 10.5)	No
Oesophagus (C15)	1.4	1.5	2.0	1.4	1.7	1.1	1.3	1.5	1.4	-1.7 (-6.0, 2.7)	No
Stomach (C16)	13.2	15.9	15.9	15.6	18.5	17.9	17.0	15.8	11.1	-2.7 (-6.4, 1.3)	Yes (2010)
Colorectum (C18-20)	11.8	11.4	17.9	17.1	20.6	20.5	16.9	17.1	13.2	2.8 (-4.9, 11.1)	Yes (2008)
Liver (C22)	4.2	4.7	3.2	4.1	6.5	7.7	5.8	6.4	4.0	2.9 (-5.9, 12.5)	No
Pancreas (C25)	1.0	1.6	1.0	1.2	1.9	1.6	1.2	1.1	0.7	-4.5 (-13.4, 5.4)	No
Larynx (C32)	0.2	0.4	0.7	0.8	0.5	0.2	0.5	0.3	0.2	-8.7 (-21.4, 6.0)	No
Lung & bronchus (C33-34)	11.4	13.6	14.3	14.6	16.7	19.6	16.5	20.7	16.7	5.0 (0.9, 9.3)	No
Other skin (C44)	2.0	2.4	2.1	3.3	2.1	2.0	1.7	1.6	1.2	-7.4 (-13.7, -0.6)	No
Breast (C50)	31.0	32.1	44.1	39.0	49.2	44.9	41.4	33.0	33.9	-0.8 (-6.0, 4.8)	No
Cervix uteri (C53)	10.3	10.2	10.2	12.5	11.5	10.8	14.8	10.7	13.0	2.8 (-1.4, 7.3)	No
Corpus uteri (C54)	3.0	3.5	3.6	4.0	4.3	2.3	2.8	2.8	3.5	-1.8 (-7.2, 4.0)	No
Ovary (C56)	4.5	7.4	4.9	5.8	8.5	8.4	8.4	6.2	7.0	2.6 (-4.0, 9.6)	No
Kidney (C64)	0.6	0.7	0.7	1.1	1.3	0.7	0.8	0.8	0.5	-0.6 (-10.7, 10.7)	No
Bladder (C67)	0.9	1.0	1.0	1.1	0.8	1.2	1.2	1.0	0.8	-0.5 (-6.0, 5.3)	No
Brain, nervous system (C70-72)	1.2	1.0	0.7	1.1	2.1	1.8	1.5	1.6	1.2	3.5 (-5.9, 13.9)	No
Thyroid (C73)	6.9	6.6	11.5	10.3	13.7	16.4	10.9	13.8	12.0	5.5 (-1.7, 13.3)	No
Non-Hodgkin lymphoma (C82-85, C96)	4.0	5.4	5.0	4.8	6.8	4.9	4.5	4.9	3.1	-3.3 (-9.6, 3.4)	No
Leukaemia (C91-95)	3.5	4.7	4.5	6.3	4.9	7.9	2.4	3.2	2.3	-7.3 (-19.4, 6.8)	No
Others	12.3	14.2	14.6	14.5	14.8	17.0	14.4	13.3	12.3	-0.8 (-3.0, 1.5)	Yes (2009)
All (C00-C96 without C44)	127.2	142.4	164.8	161.2	197.0	194.8	171.8	161.7	144.1	1.9 (-0.7, 4.6)	Yes (2008)

*AAPCs 95% CI indicated a significant difference from 0 at alpha=0.05 level.